Evidence map›Paper›PMID 40109397›Full record

ArticleJuntendo medical journal2025

Development of Functional Recovery Therapy for Post-Stroke Sequelae: Towards a Future without Stroke Aftereffects.

Nobukazu Miyamoto, Nobutaka Hattori

Abstract read
In one paragraph

Article in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nobukazu Miyamoto
Nobutaka Hattori

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke remains a leading cause of mortality and morbidity globally, posing significant challenges to healthcare systems due to its impact on Activities of Daily Living, Quality of Life, and healthcare costs. Current treatments primarily focus on acute management through thrombolytic therapy and thrombectomy, but only a limited number of patients benefit, underscoring the need for effective therapies to aid chronic stroke recovery. Despite ongoing clinical trials, cell therapy faces substantial logistical and cost-related hurdles, limiting its widespread adoption. Strategies to minimalize post-stroke sequelae emphasize preventing cerebral infarction deterioration, utilizing predictive scoring systems for focused treatment, and exploring drug repositioning. The complex interplay within the Neurovascular Unit and Oligovascular Niche highlights the role of various cell types and neurotrophic factors in stroke pathophysiology and recovery phases. Notably, microglia and astrocytes exhibit dual phenotypes ─ either inflammatory or protective ─ depending on the environment, influencing neural damage or repair processes post-stroke. Mitochondrial therapy emerges as a promising avenue, leveraging the organelles' ability to migrate between cells and mitigate inflammatory responses. Studies suggest that mitochondria transferred from astrocytes or other sources could transform inflammatory astrocytes into protective ones, thereby promoting white matter integrity and potentially reducing dementia progression associated with stroke sequelae. In conclusion, addressing stroke's multifaceted challenges requires innovative therapeutic approaches targeting inflammatory mechanisms and enhancing neuroprotection. Early detection and intervention, coupled with advancements in mitochondrial therapy and understanding intercellular interactions, hold promise for improving stroke outcomes and reducing long-term neurological complications.

Indexed as

cell-cell interactioncerebral infarctionmitochondrial treatmentneurovascular unitpost-stroke sequelae

Identifiers

PMID40109397
PMCPMC11915467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.